H P Gerber

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo
    Gieri Camenisch
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:17281-90. 2002
  2. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
  3. ncbi Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    Hans Peter Gerber
    Departments of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 65:671-80. 2005
  4. ncbi The role of VEGF in normal and neoplastic hematopoiesis
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 81:20-31. 2003
  5. ncbi Angiogenesis and bone growth
    H P Gerber
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Trends Cardiovasc Med 10:223-8. 2000
  6. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
  7. ncbi The role of vascular endothelial growth factor in angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, Calif 94080, USA
    Acta Haematol 106:148-56. 2001
  8. ncbi Vascular endothelial growth factor is essential for corpus luteum angiogenesis
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nat Med 4:336-40. 1998
  9. ncbi Angiogenesis-independent endothelial protection of liver: role of VEGFR-1
    Jennifer LeCouter
    Departments of Molecular Oncology, Protein Engineering, and Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 299:890-3. 2003
  10. ncbi Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice
    S P Williams
    Genentech, Inc, 1 DNA Way 72A, South San Francisco, CA 94080, USA
    J Magn Reson Imaging 14:374-82. 2001

Collaborators

Detail Information

Publications36

  1. ncbi ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo
    Gieri Camenisch
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 277:17281-90. 2002
    ..Taken together, our data demonstrate that ANGPTL3 is the first member of the angiopoietin-like family of secreted factors binding to integrin alpha(v)beta(3) and suggest a possible role in the regulation of angiogenesis...
  2. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
    ..Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis...
  3. ncbi Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    Hans Peter Gerber
    Departments of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 65:671-80. 2005
    ..Finally, safety pharmacology studies with bevacizumab in cynomolgus monkeys showed that this agent is generally well tolerated with no unexpected adverse events...
  4. ncbi The role of VEGF in normal and neoplastic hematopoiesis
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 81:20-31. 2003
    ....
  5. ncbi Angiogenesis and bone growth
    H P Gerber
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Trends Cardiovasc Med 10:223-8. 2000
    ..The fundamental importance of chondrocytes in the growth, development and repair of the skeleton has led to intense investigation of the mechanisms that regulate chondrocyte maturation and apoptosis...
  6. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  7. ncbi The role of vascular endothelial growth factor in angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, Calif 94080, USA
    Acta Haematol 106:148-56. 2001
    ..Substantial evidence also implicates VEGF in tumors and intraocular neovascular syndromes. Currently, several clinical trials are ongoing to test the hypothesis that inhibition of VEGF activity may be beneficial for these conditions...
  8. ncbi Vascular endothelial growth factor is essential for corpus luteum angiogenesis
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nat Med 4:336-40. 1998
    ..Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia...
  9. ncbi Angiogenesis-independent endothelial protection of liver: role of VEGFR-1
    Jennifer LeCouter
    Departments of Molecular Oncology, Protein Engineering, and Pathology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 299:890-3. 2003
    ..Thus, VEGFR-1 agonists may have therapeutic potential for preservation of organ function in certain liver disorders...
  10. ncbi Dobutamine stress cine-MRI of cardiac function in the hearts of adult cardiomyocyte-specific VEGF knockout mice
    S P Williams
    Genentech, Inc, 1 DNA Way 72A, South San Francisco, CA 94080, USA
    J Magn Reson Imaging 14:374-82. 2001
    ..A prolonged high-dose dobutamine challenge was monitored by MRI. A maximal response was sustained for 90 minutes, suggesting that it did not depend on endogenous glycogen stores...
  11. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
    ..Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium...
  12. ncbi Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 272:23659-67. 1997
    ..These findings indicate that, unlike the KDR/Flk-1 gene, the Flt-1 receptor gene is directly up-regulated by hypoxia via a hypoxia-inducible enhancer element located at positions -976 to -937 of the Flt-1 promoter...
  13. ncbi Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
    Farbod Shojaei
    Genentech, Inc, 1 DNA Way, S San Francisco, California 94080, USA
    Nat Biotechnol 25:911-20. 2007
    ..These findings indicate that, in our models, refractoriness to anti-VEGF treatment is determined by the ability of tumors to prime and recruit CD11b+Gr1+ cells...
  14. pmc Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies
    Hans Peter Gerber
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 104:3478-83. 2007
    ..However, higher-affinity antibodies were more likely to result in glomerulosclerosis during long-term treatment...
  15. ncbi Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF
    Wei Ching Liang
    Department of Protein Engineering, Genentech Inc, South San Francisco, CA 94080, USA
    J Biol Chem 281:951-61. 2006
    ..Thus, the functional contribution of stromal VEGF varies greatly among tumors, and systemic blockade of both tumor and stroma-derived VEGF is sufficient for inhibiting the growth of tumor xenografts...
  16. ncbi Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice
    Ajay K Malik
    Department of Pathology, Genentech, South San Francisco, CA 94080, USA
    Blood 107:550-7. 2006
    ..The absence of compensatory VEGFR-1 signaling by VEGF-B and PlGF may have important implications for the development of anticancer strategies targeting the VEGF ligand/receptor system...
  17. ncbi Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    Frank A Scappaticci
    Genentech, Inc, BioOncology, 455 East Grand Ave, South San Francisco, CA 94080, USA
    J Natl Cancer Inst 99:1232-9. 2007
    ..Low-dose aspirin was permitted in these trials, and its safety was also analyzed...
  18. pmc VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis
    Jianying Dong
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    EMBO J 23:2800-10. 2004
    ..Thus, PDGFR alpha signaling is required for the recruitment of VEGF-producing stromal fibroblasts for tumor angiogenesis and growth. Our findings highlight a novel aspect of PDGFR alpha signaling in tumorigenesis...
  19. ncbi Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:391-400. 2004
  20. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  21. ncbi Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma
    Max L Tejada
    Department of Molecular Oncology, Pathology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 12:2676-88. 2006
    ..We propose that therapies targeting this stromal cell type may be effective in treating certain types of solid tumors...
  22. ncbi Anti-CD30 diabody-drug conjugates with potent antitumor activity
    Kristine M Kim
    Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Mol Cancer Ther 7:2486-97. 2008
    ..Diabody-drug conjugates can have potent antitumor activity at well-tolerated doses and warrant further optimization for cancer therapy...
  23. doi Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
    Charlotte F McDonagh
    Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Mol Cancer Ther 7:2913-23. 2008
    ..The strategy used here for enhancing the therapeutic index of antibody-drug conjugates is independent of the antigen-binding variable domains and potentially applicable to other antibodies...
  24. ncbi Angiogenesis: new opportunities and solutions for drug development. Predictive markers for antiangiogenic drugs
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
    Expert Opin Investig Drugs 12:2001-4. 2003
  25. ncbi Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells
    Boris A Hesser
    Department of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA
    Blood 104:149-58. 2004
    ....
  26. pmc VEGF inhibition and renal thrombotic microangiopathy
    Vera Eremina
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    N Engl J Med 358:1129-36. 2008
    ..These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy...
  27. ncbi VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis
    Masahiro Inoue
    Department of Biochemistry and Biophysics, Diabetes and Comprehensive Cancer Centers, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Cell 1:193-202. 2002
    ..Thus, VEGF-A is crucial for angiogenesis in a prototypical model of carcinogenesis, whose loss is not readily compensated...
  28. ncbi Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis
    Hiroaki Yamamoto
    Department of Medicine and Lung Biology Center, University of California, San Francisco, CA 94143, USA
    Dev Biol 308:44-53. 2007
    ....
  29. pmc Corneal avascularity is due to soluble VEGF receptor-1
    Balamurali K Ambati
    Department of Ophthalmology, Medical College of Georgia and Augusta Veterans Affairs Medical Center, Augusta, Georgia 30907, USA
    Nature 443:993-7. 2006
    ....
  30. ncbi Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor
    Sabine Raab
    Max Plank Institut für physiologische und klinische Forschung, Bad Nauheim, Germany
    Thromb Haemost 91:595-605. 2004
    ..VEGF acts as a key regulator of brain angiogenesis and provides instructive cues for the correct spatial organization of the vasculature...
  31. ncbi Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback
    Yoh suke Mukouyama
    Division of Biology 216 76, California Institute of Technology, 1201 E California Boulevard, Pasadena, CA 91125, USA
    Development 132:941-52. 2005
    ..Different mechanisms therefore probably underlie these endothelial patterning and differentiation processes...
  32. ncbi Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis
    Nan Tang
    Molecular Biology Section, Division of Biological Sciences, University of California, San Diego, San Diego, California 92093, USA
    Cancer Cell 6:485-95. 2004
    ..We thus show that a HIF-1alpha-driven, VEGF-mediated autocrine loop in EC is an essential component of solid tumor angiogenesis...
  33. ncbi Capillary regression in vascular endothelial growth factor-deficient skeletal muscle
    Kechun Tang
    Division of Physiology, Department of Medicine, University of California, San Diego, La Jolla, California 92093 0623, USA
    Physiol Genomics 18:63-9. 2004
    ..These data implicate VEGF as an essential survival factor for muscle capillarity and also demonstrate insufficient VEGF-dependent signaling leads to apoptosis in mouse skeletal muscle...
  34. pmc Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
    Vera Eremina
    The Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Invest 111:707-16. 2003
    ..Our data demonstrate that tight regulation of VEGF-A signaling is critical for establishment and maintenance of the glomerular filtration barrier and strongly supports a pivotal role for VEGF-A in renal disease...
  35. ncbi The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation
    Ganka Nikolova
    Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany
    Dev Cell 10:397-405. 2006
    ..The proposed mechanism explains why beta cells must interact with endothelial cells, and it may apply to other cellular processes in which endothelial signals are required...
  36. ncbi Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
    Ezogelin Oflazoglu
    Department of Translational Biology, Seattle Genetics, WA 98021, USA
    Blood 110:4370-2. 2007
    ..These findings may have implications for patient stratification or combination treatment strategies in clinical trials conducted with SGN-30 in HD and ALCL...